The study was planned to compare, in a prospective double-blind randomized trial, the efficacy and safety of toremifene (TOR) and tamoxifen (TAM) in post-menopausal patients with advanced breast cancer who have not had prior systemic therapy for advanced disease. Four hundred and fifteen post-menopausal patients with oestrogen receptor (ER)-positive or ER-unknown advanced breast cancer were randomly assigned to receive daily either 60 mg TOR or 40 mg TAM. The patients were stratified to measurable and non-measurable but evaluable groups. They were assessed for response to therapy, time to progression (TTP), time to treatment failure (TTF), response duration, overall survival and drug toxicity. Two hundred and fourteen patients were randomized into TOR and 201 into TAM treatment. The response rate (complete + partial) was 31.3% for TOR and 37.3% for TAM (P = 0.215). The 95% confidence interval (Cl) for the 6% difference was -15.1% to 3.1%. The median TTP was 7.3 months for TOR and 10.2 months for TAM (P = 0.047). The 95% Cl for the hazard ratio of 0.80 was 0.64-1.00. A percentage of the TOR patients (9.8%) and the TAM patients (18.9%) discontinued the treatment prematurely (P = 0.011) for various reasons. Consequently, the median TTF of 6.3 vs 8.5 months did not differ significantly (P = 0.271). The hazard ratio was 0.89 and the subsequent 95% Cl 0.73-1.09. The median overall survival was 33.0 months for TOR and 38.7 months for TAM (P = 0.645). The hazard ratio was 0.94 with 95% Cl of 0.73-1.22. The transient difference in TTP may be related to an imbalance in ER content of the tumours. When only patients with ER-positive tumours were considered (n = 238), no difference between two treatments was seen (P = 0.578). TAM was associated with an overall slightly higher frequency of adverse drug reactions than TOR (44.3 vs 39.3%) and a higher discontinuation rate due to these events (3.5% vs 0.9%). Treatment-emerged moderate dizziness (P = 0.026) and cataracts (P = 0.026) were more frequent among TAM than among TOR patients. In conclusion, TOR (60 mg day1) and TAM (40 mg day-1) are equally effective and safe in the treatment of advanced post-menopausal ER-positive or ER-unknown breast cancer.
Tamoxifen (TAM) is the most common alternative for initial endocrine therapy of patients with recurrent or metastatic breast cancer. The overall response rate of post-menopausal women to TAM varies from 20% to 60% (Jaiyesimi et al, 1995) . This wide range is largely due to the variability of prognostic factors in different study populations and to heterogeneous quality assessment. TAM, when given as an adjuvant treatment, is associated with a 20% mortality reduction (Santen et al, 1990; Early Breast Cancer Trialists' Collaborative Group, 1992) .
The presence of oestrogen receptors (ERs) in the breast cancer cells is the most important factor associated with successful treatment with TAM. Approximately 70% of al primary breast cancers in post-menopausal women contain ER and tumour growth is dependent on oestrogens. TOR and TAM have both oestrogenic and antioestrogenic effects which are dependent on species, gender, time of treatment, organ and end point of measurement (Kangas, 1992a) .
Generally TAM is well tolerated. The most common adverse drug reaction consists in climacteric-like symptoms, but the drug has also been reported to generate DNA adducts in human hepatocyte cultures and in rats and Syrian hamsters (Han et al, 1992; White et al, 1992; Hard et al, 1993) . TAM is a liver carcinogen in rats (Hirsimaki et al, 1993; Vancutsem et al, 1994) and it increases the risk of endometrial and gastrointestinal cancers in patients (Fisher et al, 1994 ; De Gregorio et al, 1995; Rutqvist et al, 1995) and increases the number of polyps in the endometrium (Lahti et al, 1993) . Clearly, an anti-oestrogen that lacks these carcinogenic characteristics while retaining the beneficial effects of TAM is desirable (Zito, 1994) .
Toremifene (TOR) is a new antioestrogen and a pharmacological analogue of TAM (Kangas, 1992b; Kivinen and Maenpaa, 1990) having both oestrogenic and antioestrogenic properties . In breast cancer, TOR blocks the oestrogenmediated growth stimulus of tumour cells ) by a mechanism that includes the regulation of oncogene expression and growth factors and induction of apoptosis (Vuorio et al, 1988; Warri et al, 1993) .
The toxicology of TOR resembles that of TAM, except for the carcinogenicity, which is less than that of tamoxifen according to animal studies. Nor does TOR generate DNA adducts in the rat liver (White et al, 1992; Hard et al, 1993) . In a 2-year study in rats TOR was not carcinogenic (Karlsson et al, 1996) .
More than 1000 post-menopausal breast cancer patients have been included in ongoing and completed phase II studies with TOR. The dose has ranged from 20 mg to 400 mg day-' (Valavaara et al, 1988; Valavaara and Pyrhonen, 1989; Hietanen et al, 1990; Pyrhonen et al, 1990; Hamm et al, 1991) . TOR has been used as first-, second-or third-line treatment after previous hormonal or cytotoxic treatment has failed (Valavaara et al, 1988; Valavaara and Pyrhonen, 1989; Hietanen et al, 1990; Pyrhonen et al, 1990; Hamm et al, 1991; Jonsson et al, 1991; Tominaga et al, 1993; Vogel et al, 1993; Pyrhonen et al, 1994) . At a dose of 40-240 mg day-', TOR has been well tolerated as first-line treatment in advanced ER-positive or undetermined breast cancer. The response rates have ranged between 43% and 61% (Valavaara et al, 1988; Hietanen et al, 1990; Tominaga et al, 1993) . Consequently, a few large phase III studies were initiated comparing tamoxifen with toremifene (Pyrhonen, 1990; Hayes et al, 1995) .
The aim of the present study was to compare the safety and efficacy of TOR 60 mg day-' with TAM 40 mg day-' in the treatment of post-menopausal patients with advanced breast cancer.
PATIENTS AND METHODS Study design
This study is a double-blind, parallel group, randomized multicentre clinical study. A total of 415 women were enrolled in 26 centres in six countries. The study was initiated in Finland in 1986.
Later, it was extended to Sweden, Norway, Poland, Hungary and the Czech Republic.
Patient eligibility
Eligible patients were post-menopausal (I year since the last menstruation or age 55 years if a hysterectomy had been performed) and had histologically or cytologically verified inoperable primary, metastatic or recurrent breast cancer with at least one measurable or evaluable (bone disease) lesion. ER status had to be positive or unknown. Prior adjuvant therapy was allowed if at least 12 months had elapsed since the last endocrine treatment or the patient had fully recovered from cytotoxic therapy. The anticipated survival had to be at least 3 months and the Karnofsky performance status . 50%. Patients were excluded if they had severe concomitant renal, hepatic, cardiac, diabetic or thromboembolic diseases or other malignancies; basal cell cancer of the skin or cervical carcinoma in situ were allowed. Continuous use of corticosteroids for diseases other than cancer was allowed only if it had been started 6 months before randomization. Patients who were not considered able to cooperate were also excluded. Written or documented verbal informed consent was required. The study was approved by the ethics committees in each participating hospital.
Randomization and treatment
The patients were stratified by whether or not they had measurable or only evaluable disease and were randomly assigned to treatment with TOR or TAM. Randomization was performed centrally, using computer generated lists that were prepared separately for both stratification groups and for each participating centre.
The study medications were provided by Orion-Farmos as tablets containing either 60 mg of TOR or 40 mg of TAM. The dose of TAM was chosen on the basis of clinical practice in Scandinavia and the dose of TOR was based on the previous phase II results (Valavaara et al, 1988) . The dosage for both arms was one tablet by mouth daily, preferably at breakfast time. The treatment continued until disease progression or adverse events precluded the use of the drug. Minimum treatment period was 2 months. The patients were required to return all unused tablets, which were counted and recorded to assess treatment compliance.
Patient evaluation and response criteria
All patients had a complete history and physical examination no earlier than 4 weeks before the treatment: blood chemistry, haemoglobin, a leucocyte and platelet count, a chest radiograph, a skeletal scintigraphy, an abdominal sonography or computerized tomography (CT) scan and assessment of performance status. If the scintigraphy revealed bone metastasis, a radiograph was then obtained to verify the finding. All lesions, signs and symptoms were registered.
The follow-up examinations were performed bimonthly for 2 years and thereafter at 4-month intervals. At each follow-up a careful clinical examination was done and the same blood tests were taken as at baseline. In case of multiple bone metastasis, at least four and invariably more than 30% of the lesions were evaluated bimonthly except for the skeletal scintigraphy which was taken every fourth month. In case of a negative baseline result, a chest radiograph, an abdominal sonography or CT scan and skeletal scintigraphy were performed twice annually. All adverse events were registered and the degree of causality to the study drug was evaluated.
The study met the GCP standards with 100% source data verification during the study. The responses were evaluated according to the WHO criteria adopted by the UICC (Miller et al, 1981) . Treatment response (CR, PR, NC) was accepted only if confirmed at two consecutive evaluations 2 months apart. All objective responses and the duration of the response were re-evaluated and approved by the investigator's review board. Time to progression (TTP) was defined as the time between randomization and onset of relapse or disease progression. Patients who had discontinued the study prematurely and patients who were still continuing in the study were treated as censored observations from the time of randomization until the time of discontinuation, or until the time of the latest follow-up visit (before 31 December 1993) respectively. Time to treatment failure (TTF) was defined as the period from the day of randomization to the day when disease progression, treatment-related toxicity, resulting in discontinuation of therapy or death (from any cause) occurred. Table 1 . These characteristics are evenly balanced between the two arms except for the levels of ER receptors: in the TAM group a larger proportion of patients had high ER levels, which is reflected by mean ER concentrations (119 and 171 fmol mg-' cytosol protein for TOR and TAM patients respectively).
Response
Response data are presented in Table 2 . The response rates were calculated for all randomized patients as well as for all eligible and all evaluable patients separately. There were 19 complete responses in both treatment arms and 48 vs 56 partial responses with TOR and TAM arm respectively. The rates of complete plus partial responses for TOR and TAM were 31.3% and 37.3% respectively. The difference was not statistically significant (P = 0.215). The 95% CI for the difference was -15.1% to 3.1%.
The median time to the onset of objective response for all randomized patients was 3.9 months with TOR and 2.6 months with TAM (P = 0.455). The median duration of complete and amn months from randomization; bp = 0.047 (Figure 2) and the difference was mainly due to the effects encountered in patients with tumours of unknown ER status. For these patients the median TTP on TOR was 6.3 months (95% Cl 4.4-8.0) and on TAM 11.4 months (95% Cl 8.1-14.4) (P = 0.019), whereas for the patients with ER-positive tumours the TTP was 9.1 (95% CI 4.6-11.6) and 10.1 months (95% Cl 6.5-12.5) (P = 0.578). With regard to TTF, the ER status yielded analogous P-values of 0.103 and 0.984 respectively.
Survival
Of the 415 randomized patients, 238 had died by the data cut-off date; 123 patients in the TOR arm and 115 in the TAM arm. Survival data are presented in Table 3 and Figure 3 . The median survival time for patients treated with TOR was 33.0 months (95% CI 28.5-37.0) and 38.7 months (95% CI 31.8-41.9) for those treated with TAM (P = 0.645).
British Journal of Cancer (1997) 76(2) aNumber (%) of patients; bby WHO severity grading; cp = 0.048; dp = 0.026. aNumber (%) of patients; bo (0.0) and 5 (2.5) cataracts respectively, P = 0.026; cabnormality criteria: > 2.5 times the upper limit of reference range; dp = 0.042; eabnormality criteria: > 1.25 times the upper limit of reference range. The reasons for premature study drug discontinuations are presented in Table 5 . A total of 21 (9.8%) patients discontinued TOR and 38 patients (18.9%) TAM, for various reasons (P = 0.011). Two of the TOR patients (0.9%) vs seven of the TAM patients (3.5%) discontinued the treatment due either to toxicity or to refusal.
Other treatment emergent adverse events are listed in Table 6 . Five patients developed cataracts while on TAM and none on TOR (P = 0.026). Of the 13 other malignancies detected before the data cut-off date, five were found among TOR patients and eight among TAM patients. One endometrial carcinoma and two ovarian cyst malignancies were observed among TAM patients, but no gynaecological malignancies among TOR patients. Otherwise, the distribution of other malignancies was very similar. Elevated liver enzyme, SGOT, was observed more frequently among TAM patients than TOR patients (P = 0.042). The difference was still of borderline significance (P = 0.082), when excluding the one patient in TOR and three patients in the TAM group with liver metastases.
There was no difference concerning fatal disorders (Table 7) during or within 1 month after discontinuation of the treatment. The majority of the deaths were due to metastatic breast cancer and not related to treatment itself. There were no deaths directly associated with the study drugs.
British Journal of Cancer (1997) The performance status and body weights of the patients were similar in the treatment groups throughout the study.
DISCUSSION
This multicentre phase III study with two parallel groups compared the efficacy and safety profile of TOR (60 mg daily) with TAM (40 mg daily) as first-line treatment of inoperable primary or metastatic ER-positive or undetermined breast cancer in post-menopausal women. This is the only large-scale doubleblind trial comparing these two drugs (Pyrhonen, 1990) . The primary study variables were response rate, TTP, overall survival and safety. In addition, variables such as TTF, time to onset of response and response duration were followed. The response rate was slightly higher for patients on TAM, but the difference was not statistically significant. The strict criteria for efficacy assessment and the great proportion of patients (43%) with tumours of unknown ER status may explain the relatively low proportion of objective responses in both treatment groups compared with those encountered in the earlier phase II studies with TOR (Valavaara et al, 1988; Hietanen et al, 1990; Tominaga et al, 1993) .
At the time of closing the database for analysis, 19 patients continued the treatment with TOR and 20 with TAM. The TTP plot was in favour of TAM, but suggests a transient, rather than a persistent difference between the treatment groups. Subgroup analysis shows that the difference was essentially generated in the patient group with tumours of unknown ER status. There was no difference between the treatment groups if the patient population with ER-positive tumours (n = 238) is considered separately. There was, evidently, some major imbalance in receptor levels or some other prognostic factors among the patients with unknown ER status when compared with ER-positive tumour patients, because the TTP was longer in the ER unknown group of TAM patients (median 11.4 vs 10.1 months). As expected, the TTP was shorter in TOR-treated patients with ER-unknown than ERpositive tumours (median 6.3 vs 9.1 months). In previous studies, positive correlation between ER concentration and TTP as well as response duration has been reported for various hormonal treatments of breast cancer (Bonomi et al, 1988; Valavaara et al, 1990) . In addition, the ER concentrations were higher in the TAM patients with known ER status in the present study. Considering that more patients on TAM than on TOR discontinued the study prematurely, the TTF did not differ between the treatment groups.
At the time of closing the database, 18 patients with objective response continued the study on TOR and 16 on TAM. There were no significant differences between the treatment groups as regards response duration or survival.
The present study indicates that in the treatment of metastatic breast cancer TAM and TOR are equally safe and effective, confirming the results of another large randomized trial (Hayes et al, 1995) . The toxicity was mostly mild or moderate and usually attributable to the antioestrogenic/oestrogenic properties of the study drugs. Significantly more patients experienced treatmentemerged dizziness and cataract in the TAM group than the TOR group. As no regularly performed eye examinations were organized in the study, the difference in the frequency of cataracts must be taken into account with great reservation. Considering previously reported ocular toxicity of tamoxifen (Gemer, 1989; Pavlidis et al, 1992; Heier et al, 1994) , this should be further explored prospectively in other trials. The higher incidence of treatment discontinuations due to toxicity or patient refusal in the TAM group, may also reflect the somewhat higher toxicity of TAM in the dose used in this study in comparison with TOR. Overall, however, both treatments were well tolerated.
Preclinical toxicity data show that TOR is not carcinogenic, whereas TAM has strong hepatocarcinogenicity in rats, which suggests, potentially, an important safety advantage for TOR. In a 2-year mouse carcinogenicity study, TOR induced tumours in the ovaries, bone and testes (to be published elsewhere). The corresponding 2-year study with TAM is not available. Because oestrogens cause similar tumours in mice, and TOR is mainly oestrogenic in this species, these tumours are considered to be species specific and to be of little clinical relevance to humans.
The widespread use of TAM in adjuvant medical therapy and even as a chemopreventive agent has raised the question of its safety in view of its carcinogenicity in animals. In adjuvant trials, TAM has been shown to increase the incidence of uterine cancers (Fornander et al, 1993; Fisher et al, 1994; De Gregorio et al, 1995; Rutqvist et al, 1995) , although the median follow-up times have been less than 10 years. The expected time from tumour initiation to clinically detectable cancer has been considered to be between 10 and 15 years. The mechanism of TAM-induced carcinogenicity may be partly hormonal (Metzler and Degen, 1987; Williams et al, 1993) , i.e. promotion of existing tumours, and partly nonhormonal, i.e. initiation of tumours or mutagenesis of p53 tumour suppressor gene (Styles et al, 1994; Vancutsem et al, 1994) . As TAM induces DNA adducts and is carcinogenic in the rat liver (Han and Liehr, 1992; Hard et al, 1993; Hirsimaki et al, 1993; Montandon et al, 1994) , non-hormonal mechanisms might be preferentially related to the initiation of secondary malignancies. The recent report that TAM-treated patients have an increased incidence of gastrointestinal tumours is disconcerting (Rutqvist et al, 1995) . Studies have now been initiated to compare the genotoxic potential of TOR with TAM in adjuvant therapy of breast cancer.
In conclusion, the results of this double blind trial suggest that TOR (60 mg day-') and TAM (40 mg day-') are equally effective in the treatment of advanced ER-positive or ER-unknown breast cancer in post-menopausal patients. The safety profile of TOR makes it an attractive alternative to TAM, especially in long-term treatment of breast cancer. The on-going comparative trials on these drugs as an adjuvant treatment will further elucidate the feasibility of TOR in lesser stages of breast cancer. Exploration on chemoprevention with TOR should also be considered.
